Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Drug resistance to tyrosine kinase inhibitors (TKIs) is a significant clinical challenge in chronic myelogenous leukemia (CML).
• Bcr-Abl protein depletion is a potential strategy to overcome TKI resistance.
• Identifying novel therapeutic targets is crucial for improving CML treatment outcomes.

Purpose of the Study:

• To investigate the efficacy of Chk1 inhibitors (AZD7762 and MK-8776) in overcoming TKI resistance in chronic myelogenous leukemia (CML).
• To elucidate the mechanism by which Chk1 inhibitors exert their antitumor effects in CML, particularly in the context of Bcr-Abl protein.
• To evaluate the therapeutic potential of Chk1 inhibitors in preclinical models of CML.

Main Methods:

• Treatment of CML cell lines (KBM5 and KBM5^T315I) and primary patient leukemia cells with Chk1 inhibitors.
• Assessment of antitumor and cytotoxic effects, apoptosis induction, and DNA damage.
• Analysis of Bcr-Abl protein degradation using proteasome inhibitors and immunoprecipitation assays to identify the role of E3 ubiquitin ligase CHIP.
• Evaluation of MK-8776 efficacy in a xenograft tumor model using KBM5^T315I cells.

Main Results:

• Chk1 inhibitors AZD7762 and MK-8776 demonstrated potent antitumor and cytotoxic effects against CML cell lines, including imatinib-resistant KBM5^T315I cells and primary CML patient cells.
• These inhibitors induced apoptosis and increased DNA damage in CML cells, accompanied by Bcr-Abl protein degradation.
• Bcr-Abl degradation was found to be mediated by ubiquitination dependent on the E3 ubiquitin ligase CHIP.
• MK-8776 significantly suppressed tumor growth in a xenograft model of imatinib-resistant CML.

Conclusions:

• Targeting Chk1 with inhibitors represents a promising strategy to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia.
• The mechanism involves Chk1 inhibitor-induced degradation of Bcr-Abl protein via the ubiquitin-proteasome pathway, dependent on CHIP.
• Chk1 inhibitors exhibit selective toxicity towards leukemia cells, sparing normal human mononuclear cells, suggesting a favorable therapeutic window.